Mikael J. Pittet,Ralph Weissleder,Sean Arlauckas,Christopher Garris
申请号：
US16495725
公开号：
US20200095323A1
申请日:
2018.03.19
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Fc-engineered variants of anti-PD1 IgG antibodies that abrogate FcγR binding and mAb effector functions, or combinations with therapies that inhibit FcγR binding in vivo, for treatment of cancer.
